Expression vector of human claudin-11 (CLDN11). Compatible with lentiviral transduction (3rd generation).
![]() Drawn by SnapGene® software |
|
| Clone info. | Expression vector of human claudin-11 (CLDN11). Compatible with lentiviral transduction (3rd generation). |
|---|---|
| Comment | BleoR is not applicable for lentivirus transduction, as it is located outside the packaging sequence. |
| Vector backbone | CSII-EF-MCS-IRES2-Venus (RDB04384) (plasmid) |
| Selectable markers | Ampicillin (E. coli). Please note that BleoR marker is not included in the lentivirus produced from this vector. |
| Growth conditions | LB, 37℃ |
| Gene/insert name | human CLDN11 cDNA. |
| Depositor|Developer | Sugimoto, Kotaro | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word Please visit Ordering instruction.[link] |
|---|---|
| Terms and conditions for distribution | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. (Onagi, A. et al., Cell Commun. Signal., 22(1):588, 2024) For use of the BIOLOGICAL RESOURCE by a for-profit organization or for use of the BIOLOGICAL RESOURCE for for-profit research by not-for-profit organization, the RECIPIENT must obtain a prior written consent from the FUKUSHIMA MEDICAL UNIVERSITY (liaison@fmu.ac.jp). Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product. |
| Remarks | Remember that you will be working with samples containing infectious virus. Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Onagi, A. et al., Cell Commun. Signal., 22(1):588, 2024)。営利機関の利用もしくは非営利学術機関による営利目的研究利用の場合は、福島県立医科大学 (liaison@fmu.ac.jp) の許可を得ること。 付加的使用条件: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。 |
| 備考 | このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。 ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。 |
| Catalog # | Resource name | Shipping form | Fee |
|---|---|---|---|
| RDB21025 | pCSII-CLDN11 | DNA solution |
Materials & Methods section:
| The pCSII-CLDN11 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB21025). |
Reference section:
| Onagi, A., Sugimoto, K., Kobayashi, M., Sato, Y., Kobayashi, Y., Yaginuma, K., Meguro, S., Hoshi, S., Hata, J., Hashimoto, Y., Kojima, Y., Chiba, H., Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression. Cell Commun. Signal 22 (1): 588 (2024). PMID 39639312. [PubMed] [Article] [RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
Original, user report and related articles
| original | Onagi, A., Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression. Cell Commun. Signal 22 (1): 588 (2024). PMID 39639312. [PubMed] [Article] [RRC of NBRP] |
|---|
Featured content